ZyVersa Therapeutics Revenue and Competitors

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases with high unmet medical needs. Our clinical pipeline includes phase 2a VAR 200, an intracellular cholesterol efflux mediator for treatment of an orphan renal disease, focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential for multiple inflammatory diseases. VAR 200, 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), preclinical studies demonstrate that it promotes cholesterol removal from podocytes, the kidney's filtering system, slowing progression of podocyte injury and renal disease. Our novel inflammasome inhibitor targets the upstream innate immune system. It inhibits the ASC component of inflammasomes, blocking intracellular initiation of the inflammatory cascade and extracellular perpetuation of inflammation.